Provention Bio Revenue and Competitors
Estimated Revenue & Valuation
- Provention Bio's estimated annual revenue is currently $15.7M per year.
- Provention Bio's estimated revenue per employee is $121,357
- Provention Bio's total funding is $238.5M.
- Provention Bio's current valuation is $301M. (January 2022)
Employee Data
- Provention Bio has 129 Employees.
- Provention Bio grew their employee count by 17% last year.
Provention Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO, President, Co-Founder and Board Director | Reveal Email/Phone |
2 | Chief Quality Officer | Reveal Email/Phone |
3 | SVP, Clinical Operations | Reveal Email/Phone |
4 | VP, Clinical Development | Reveal Email/Phone |
5 | SVP Biometrics and Clinical Development Strategy | Reveal Email/Phone |
6 | VP Communications | Reveal Email/Phone |
7 | SVP Regulatory Affairs | Reveal Email/Phone |
8 | VP, Alliance Management and Business Development | Reveal Email/Phone |
9 | VP Commercial Operations | Reveal Email/Phone |
10 | Director, Information Technology | Reveal Email/Phone |
Provention Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Provention Bio?
Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases. -We seek technologies or targets designed to predict, preempt or intervene before immune disease begins, re-appears or progresses. -We are creating a new biopharmaceutical category for autoimmunity. We leverage a transformational drug development strategy that sources, repositions and advances candidates that: -Target the interception or prevention of immune-mediated disease -Have been underdeveloped or deprioritized because of insufficient clinical trial efficacy or for strategic reasons -Have demonstrated proof-of-mechanism by preventing or intercepting immunopathologic pathways We believe that our deep understanding of immune-mediated pathophysiology, experience in translational medicine, and expertise in the design of rapid go/no-go clinical trials enables us to identify and evaluate potential therapeutic candidates for acquisition or in-licensing.
keywords:N/A
$238.5M
Total Funding
129
Number of Employees
$15.7M
Revenue (est)
17%
Employee Growth %
$301M
Valuation
N/A
Accelerator
Provention Bio News
will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Provention Bio (PRVB) Conference...
Provention Bio to Report First Quarter 2022 Financial Results on May 5, 2022. PRVB | 6 hours ago. RED BANK, N.J., April 28, 2022 /PRNewswire/ -- Provention...
RED BANK, N.J., April 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting...
RED BANK, N.J., Nov. 4, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the third quarter ended September 30, 2021 and provided a business update. "During ...
RED BANK, N.J., Nov. 4, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that Thierry Chauche will become Chief Financial Officer effective December 1, 2021 and Andrew Drechsler ...
Other Companies in Oldwick
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $238.4M | 823 | 0% | $763.8M |